New antibody drug aims to tame painful skin condition
NCT ID NCT06895499
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This early-stage trial tests a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa, a painful skin condition. The drug targets two proteins involved in inflammation to reduce flare-ups. The main goal is to check safety and see if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.